Assertion: prophylaxis | /r/HasProperty | group c
Facets:
Source sentences:
text: Johnny Mahlangu, M.B., B.Ch., from the University of Witwatersrand in Johannesburg, and colleagues randomized patients with hemophilia A without factor VIII inhibitors to receive a subcutaneous maintenance dose of emicizumab of 1.5 mg/kg of body weight/week (group A), 3 mg/kg every two weeks (group B), or no prophylaxis (group C) in a phase 3 multicenter trial.